

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	BR-033 PUS 01
-------	---	----	---	------------------------	---------------

Complete If Known

Application Number	TBA
Filing Date	August 2, 2005
First Named Inventor	Michel SCHNEIDER
Art Unit	TBA
Examiner Name	TBA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA	US 2002/0102217	08-01-2002	Nycomed Imaging AS		
AB	US 5,445,813	08-29-1995	Bracco International B.V.		
AC	US 6,139,819	10-31-2000	ImaRx Pharmaceutical Corp.		
AD	US 6,146,657	11-14-2000	ImaRx Pharmaceutical Corp.		
AE	US 6,221,337	04-24-2001	Nycomed Imaging AS		
AF	US 5,280,705	08-28-2001	Alliance Pharmaceutical Corp.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ¹ -Number-Kind Code ² (if known)			
BA	WO 91/15244		10-17-1991	Sintetica S.A.	
BB	WO 94/09829		05-11-1994	Sintetica S.A.	
BC	WO 94/01140		01-20-1994	LINDER, Rudolf et al.	
BD	WO 96/09307		03-28-1996	The Liposome Company, Inc.	
BE	WO 97/29783		08-21-1997	Nycomed Imaging AS	
BF	WO 97/40858		11-06-1997	ImaRx Pharmaceutical Corp.	
BG	WO 98/05364		02-12-1998	Nycomed Imaging AS	
BH	WO 99/08716		02-25-1999	Nycomed Imaging AS	
BI	WO 99/36104		07-22-1999	Du Pont Pharmaceuticals	
BJ	WO 02/055544		07-18-2002	Dyax Corp.	
BK	EP 1 419 789 A2		05-19-2004	Bristol-Myers Squibb Pharma. Company	
BL	EP 1 228 770 A1		08-07-2002	Bracco Research S.A.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Kind Code ²	Author	Title	Date
CA	MICHEL SCHNEIDER et al: "BR1: A New Ultrasonographic Contrast Agent Based on Sulfur Hexafluoride-Filled Microbubbles" Investigative Radiology, Vol. 30, No. 8, pages 451-457, XP612720				
CB	SIMON LOCKYER et al: "Demonstration of Flow and Platelet Dependency in a Ferric Chloride-Induced Model of Thrombosis" Journal of Cardiovascular Pharmacology, Vol. 33, No. 5, pages 718-725				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ²See Kind Codes of Publications in the United States and Foreign Countries in the Appendix of MPEP 201.4. ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leah Schlientz/	Date Considered	01/10/2010
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete If Known

Application Number	TBA
Filing Date	August 2, 2005
First Named Inventor	Michel SCHNEIDER
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	BR-033 PUS 01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CC	ERIKA BOHL KULLBERG et al: "Development of EGF-Conjugated Liposomes for Targeted Delivery of Boronated DNA-Binding Agents" <i>Bioconjugate Chem.</i> , Vol. 13, No. 4, pages 737-743		
CD	BRIAN C. EATOCK et al: "Numerical studies of the spectrum of low-intensity ultrasound scattered by bubbles" <i>J. Acoust. Soc. Am.</i> , Vol. 77, No. 5, pages 1692-1701		
CE	YEKTA OZER et al: "Influence of Freezing and Freeze-Drying on the Stability of Liposomes Dispersed in Aqueous Media," <i>Acta Pharm. Technol.</i> , 1988, pages 129-139, Vol. 34, No. 3, pages 129-139		
CF	MARTIN MACPINSTEN: "Surfactants and Polymers in Drug Delivery" Marcel Dekker, pages 56-60		
CG	MATTHEW J. HASIK et al: "Evaluation of synthetic phospholipids ultrasound contrast agents", <i>Ultrasonics</i> , 2002, pages 973-982, Elsevier Science B.V., New York, N.Y.		
CH	PCT Search Report for PCT/I/B/2004/000243, mail date 09-22-2004		

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO at www.uspto.gov or MPEP § 1.14. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leah Schlientz/	Date Considered	01/10/2010
-----------------------	------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/